ESR1 and metastatic neoplasm: In addition, prolonged AI treatment can result in point mutations in the ligand binding domain of ESR1 (mutant ESR1, mESR1), particularly in metastatic tumors, which result in constitutive activation (reviewed in [4,164,174]).